Predicted protein targets (top 16)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CYP3A4 | P08684 | 4/20 | 0.35 |
| ▸ | MEN1 | O00255 | 1/20 | 0.35 |
| ▸ | HPGD | P15428 | 1/20 | 0.35 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.35 |
| ▸ | AGBL2 | Q5U5Z8 | 1/20 | 0.35 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.32 |
| ▸ | THRB | P10828 | 2/20 | 0.32 |
| ▸ | ACHE | P22303 | 1/20 | 0.31 |
| ▸ | PKM | P14618 | 1/20 | 0.31 |
| ▸ | RXFP1 | Q9HBX9 | 1/20 | 0.31 |
| ▸ | BRD4 | O60885 | 1/20 | 0.31 |
| ▸ | POLB | P06746 | 1/20 | 0.31 |
| ▸ | RXRA | P19793 | 1/20 | 0.31 |
| ▸ | RXRB | P28702 | 1/20 | 0.31 |
| ▸ | EPHX2 | P34913 | 1/20 | 0.31 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.31 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL3140737 | 0.83 | CYP3A4 (0.44) | CYP3A4MEN1HPGDKMT2AAGBL2 | |
| SCHEMBL23364827 | 0.83 | CES2 (0.46) | CYP3A4MEN1HPGDKMT2AAGBL2 | |
| SCHEMBL4060815 | 0.82 | POLB (0.43) | CYP3A4MEN1KMT2AAGBL2CYP1A2 | |
| SCHEMBL3141897 | 0.82 | AGBL2 (0.34) | CYP3A4MEN1KMT2AAGBL2ACHE | |
| SCHEMBL28114010 | 0.79 | CYP3A4 (0.41) | CYP3A4MEN1KMT2AAGBL2THRB | |
| SCHEMBL3138059 | 0.79 | CYP3A4 (0.49) | CYP3A4HPGDACHEPOLB | |
| SCHEMBL5350749 | 0.76 | CYP3A4 (0.51) | CYP3A4HPGDKMT2APOLBSMN1; SMN2 | |
| SCHEMBL112083 | 0.76 | POLB (0.44) | CYP3A4MEN1HPGDKMT2APOLB | |
| SCHEMBL5355523 | 0.75 | KDM4E (0.41) | HPGDRXRARXRBEPHX2SMN1; SMN2 | |
| SCHEMBL22927041 | 0.74 | RAPGEF4 (0.34) | AGBL2EPHX2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 23 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-10150737-B2 | Compounds for controlling arthropods | BAYER CROPSCIENCE AKTIENGESELLSCHAFT (DE) | 2018-12-11 | — | — | US | disclosed |
| EP-3066080-B1 | NOVEL COMPOUNDS FOR COMBATING ARTHROPODS | BAYER CROPSCIENCE AG (DE) | 2018-05-09 | — | — | EP | disclosed |
| EP-3066079-B1 | NOVEL COMPOUNDS FOR COMBATING ARTHROPODS | BAYER CROPSCIENCE AG (DE) | 2018-05-09 | — | — | EP | disclosed |
| US-9758485-B2 | Compounds for controlling arthropods | BAYER CROPSCIENCE AKTIENGESELLSCHAFT (DE) | 2017-09-12 | — | — | US | disclosed |
| US-9758485-B2 | Compounds for controlling arthropods | BAYER CROPSCIENCE AKTIENGESELLSCHAFT (DE) | 2017-09-12 | — | — | US | disclosed |
| US-9758485-B2 | Compounds for controlling arthropods | BAYER CROPSCIENCE AKTIENGESELLSCHAFT (DE) | 2017-09-12 | — | — | US | disclosed |
| WO-2016174052-A1 | ANTIPARASITIC COMBINATIONS | BAYER ANIMAL HEALTH GMBH (DE) | 2016-11-03 | — | — | WO | disclosed |
| US-20160297765-A1 | NOVEL COMPOUNDS FOR CONTROLLING ARTHROPODS | ELANCO ANIMAL HEALTH GMBH (DE) | 2016-10-13 | — | — | US | disclosed |
| US-20160297765-A1 | NOVEL COMPOUNDS FOR CONTROLLING ARTHROPODS | ELANCO ANIMAL HEALTH GMBH (DE) | 2016-10-13 | — | — | US | disclosed |
| US-20160297765-A1 | NOVEL COMPOUNDS FOR CONTROLLING ARTHROPODS | ELANCO ANIMAL HEALTH GMBH (DE) | 2016-10-13 | — | — | US | disclosed |
| EP-3066080-A1 | SUBSTITUTED BENZAMIDES FOR THE TREATMENT OF ARTHROPODS | Bayer CropScience Aktiengesellschaft (DE) | 2016-09-14 | — | — | EP | disclosed |
| EP-3066079-A1 | SUBSTITUTED BENZAMIDES FOR TREATING ARTHROPODES | Bayer CropScience Aktiengesellschaft (DE) | 2016-09-14 | — | — | EP | disclosed |
| WO-2015067646-A1 | SUBSTITUTED BENZAMIDES FOR TREATING ARTHROPODES | BAYER CROPSCIENCE AG (DE) | 2015-05-14 | — | — | WO | disclosed |
| WO-2015067647-A1 | SUBSTITUTED BENZAMIDES FOR THE TREATMENT OF ARTHROPODS | BAYER CROPSCIENCE AG (DE) | 2015-05-14 | — | — | WO | disclosed |
| WO-2015067646-A1 | SUBSTITUTED BENZAMIDES FOR TREATING ARTHROPODES | BAYER CROPSCIENCE AG (DE) | 2015-05-14 | — | — | WO | disclosed |
| WO-2015067647-A1 | SUBSTITUTED BENZAMIDES FOR THE TREATMENT OF ARTHROPODS | BAYER CROPSCIENCE AG (DE) | 2015-05-14 | — | — | WO | disclosed |
| US-7169955-B2 | Perfluoroisopropylbenzene derivative | NIHON NOHYAKU CO., LTD. (JP) | 2007-01-30 | — | — | US | disclosed |
| US-20050113567-A1 | Perfluoroisopropylbenzene derivative | NIHON NOHYAKU CO., LTD. (JP) | 2005-05-26 | — | — | US | disclosed |
| US-20030187233-A1 | PERFLUOROISOPROPYBENZENE DERIVATIVE | NIHON NOHYAKU CO., LTD. (JP) | 2003-10-02 | — | — | US | disclosed |
| EP-1253128-A1 | PERFLUOROISOPROPYLBENZENE DERIVATIVES | Nihon Nohyaku Co., Ltd. (JP) | 2002-10-30 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20030187233-A1 | PERFLUOROISOPROPYBENZENE DERIVATIVE | AFF1, CBR1, RER1 | CYP3A4 223/4885MEN1 3829/4885HPGD 2129/4885 |
| US-10150737-B2 | Compounds for controlling arthropods | SERPINB6, CYP4X1, C1S | CYP3A4 194/4885MEN1 354/4885HPGD 802/4885 |
| US-20050113567-A1 | Perfluoroisopropylbenzene derivative | FFAR3, CBR3, HCAR3 | CYP3A4 197/4885MEN1 3547/4885HPGD 2620/4885 |
| US-20160297765-A1 | NOVEL COMPOUNDS FOR CONTROLLING ARTHROPODS | CYP4X1, CYP4B1, SERPINB6 | CYP3A4 163/4885MEN1 703/4885HPGD 640/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.